Eli Lilly and Company (LLY)

NYSE
Currency in USD
854.07
+24.65(+2.97%)
Real-time Data·
LLY Scorecard
Full Analysis
Has raised its dividend for 10 consecutive years
Earnings results expected in 7 days
Fair Value
Day's Range
829.21854.84
52 wk Range
677.09972.53
Key Statistics
Edit
Prev. Close
829.42
Open
835.07
Day's Range
829.21-854.84
52 wk Range
677.09-972.53
Volume
1.23M
Average Vol. (3m)
3.68M
1-Year Change
11.2%
Book Value / Share
15.76
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
LLY Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1,008.64
Upside
+18.10%
Members' Sentiments
Bearish
Bullish
ProTips
10 analysts have revised their earnings downwards for the upcoming period
Show more

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Employees
47000

Eli Lilly and Company SWOT Analysis


Analyst Optimism
Discover why analysts maintain bullish outlook on Eli Lilly, with price targets ranging from $970 to $1,250, reflecting strong growth prospects and market position
Pipeline Potential
Delve into Eli Lilly's promising pipeline, including oral GLP-1 agonist orforglipron, poised to revolutionize diabetes and obesity treatment markets
Financial Forecast
Explore Eli Lilly's robust 2025 guidance, projecting revenues between $58-61 billion, surpassing consensus estimates and reflecting confidence in growth trajectory
GLP-1 Market Leade
Eli Lilly's dominance in diabetes and obesity treatments, driven by Mounjaro and Zepbound, propels impressive 32% revenue growth despite recent challenges
Read full SWOT analysis

Compare LLY to Peers and Sector

Metrics to compare
LLY
Peers
Sector
Relationship
P/E Ratio
72.0x9.5x−0.5x
PEG Ratio
0.690.000.00
Price / Book
53.8x1.8x2.6x
Price / LTM Sales
16.9x3.4x2.9x
Upside (Analyst Target)
22.5%83.0%57.2%
Fair Value Upside
Unlock17.6%8.9%Unlock

Analyst Ratings

25 Buy
3 Hold
1 Sell
Ratings:
29 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1,008.64
(+18.10% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 11.76%
Dividend Yield
0.72%
Industry Median 1.73%
Annualized Payout
6.00
Paid quarterly
5-Years Growth
+15.05%
Growth Streak

Earnings

Latest Release
Feb 06, 2025
EPS / Forecast
5.32 / 5.30
Revenue / Forecast
13.53B / 13.78B
EPS Revisions
Last 90 days

People Also Watch

349.43
MSTR
+1.07%
427.09
UNH
-0.20%
78.75
MRK
+0.01%
105.92
NVDA
+3.13%
186.29
AVGO
+5.30%

FAQ

What Is the Eli Lilly (LLY) Stock Price Today?

The Eli Lilly stock price today is 854.07

What Stock Exchange Does Eli Lilly Trade On?

Eli Lilly is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Eli Lilly?

The stock symbol for Eli Lilly is "LLY."

Does Eli Lilly Pay Dividends? What’s The Current Dividend Yield?

The Eli Lilly dividend yield is 0.72%.

What Is the Eli Lilly Market Cap?

As of today, Eli Lilly market cap is 765.37B.

What is Eli Lilly Earnings Per Share?

The Eli Lilly EPS is 11.76.

What Is the Next Eli Lilly Earnings Date?

Eli Lilly will release its next earnings report on May 01, 2025.

From a Technical Analysis Perspective, Is LLY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.